Ekso Bionics to Report First Quarter 2025 Financial Results on May 5 – Conference Call to Follow
Ekso Bionics (Nasdaq: EKSO), a leader in exoskeleton technology for medical and industrial applications, has scheduled its Q1 2025 financial results announcement for May 5, 2025, after market close.
The company will host a conference call on the same day at 1:30 PM Pacific Time (4:30 PM Eastern Time) to discuss:
- First quarter 2025 financial performance
- Recent business developments
- Company updates
Interested participants can join the conference call by dialing:
The presentation will be broadcast live and archived on the company's investor relations website at www.eksobionics.com under the "Presentations & Events" section.
Ekso Bionics (Nasdaq: EKSO), leader nella tecnologia degli esoscheletri per applicazioni mediche e industriali, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 5 maggio 2025, dopo la chiusura del mercato.
La società terrà una conference call lo stesso giorno alle 13:30 ora del Pacifico (16:30 ora della costa Est) per discutere di:
- Performance finanziaria del primo trimestre 2025
- Recenti sviluppi aziendali
- Aggiornamenti sulla società
Gli interessati possono partecipare alla conference call chiamando:
- Italia: 877-407-6184
- Internazionale: 201-389-0877
La presentazione sarà trasmessa in diretta e archiviata sul sito web delle relazioni con gli investitori della società all'indirizzo www.eksobionics.com nella sezione "Presentazioni & Eventi".
Ekso Bionics (Nasdaq: EKSO), líder en tecnología de exoesqueletos para aplicaciones médicas e industriales, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 5 de mayo de 2025, después del cierre del mercado.
La compañía realizará una llamada conferencia ese mismo día a la 1:30 PM hora del Pacífico (4:30 PM hora del Este) para discutir:
- Desempeño financiero del primer trimestre de 2025
- Desarrollos recientes del negocio
- Actualizaciones de la empresa
Los interesados pueden unirse a la llamada conferencia marcando:
- Nacional: 877-407-6184
- Internacional: 201-389-0877
La presentación será transmitida en vivo y archivada en el sitio web de relaciones con inversionistas de la compañía en www.eksobionics.com, en la sección "Presentaciones y Eventos".
Ekso Bionics (나스닥: EKSO)는 의료 및 산업용 외골격 기술 분야의 선두주자로, 2025년 5월 5일 시장 마감 후 2025년 1분기 재무 실적 발표를 예정하고 있습니다.
회사는 같은 날 태평양 표준시 오후 1시 30분 (동부 표준시 오후 4시 30분)에 컨퍼런스 콜을 개최하여 다음 사항을 논의할 예정입니다:
- 2025년 1분기 재무 성과
- 최근 사업 동향
- 회사 업데이트
참석을 원하시는 분들은 다음 번호로 전화하여 컨퍼런스 콜에 참여할 수 있습니다:
- 국내: 877-407-6184
- 국제: 201-389-0877
발표 내용은 회사 투자자 관계 웹사이트 www.eksobionics.com의 "프레젠테이션 및 이벤트" 섹션에서 실시간 중계 및 아카이브됩니다.
Ekso Bionics (Nasdaq : EKSO), un leader dans la technologie des exosquelettes pour les applications médicales et industrielles, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le 5 mai 2025, après la clôture du marché.
L'entreprise organisera une conférence téléphonique le même jour à 13h30 heure du Pacifique (16h30 heure de l'Est) pour discuter de :
- La performance financière du premier trimestre 2025
- Les développements récents de l'entreprise
- Les mises à jour de la société
Les personnes intéressées peuvent rejoindre la conférence téléphonique en composant :
- National : 877-407-6184
- International : 201-389-0877
La présentation sera diffusée en direct et archivée sur le site des relations investisseurs de la société à l'adresse www.eksobionics.com dans la section « Présentations & Événements ».
Ekso Bionics (Nasdaq: EKSO), ein führendes Unternehmen im Bereich der Exoskelett-Technologie für medizinische und industrielle Anwendungen, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 5. Mai 2025 nach Börsenschluss angekündigt.
Das Unternehmen wird am selben Tag um 13:30 Uhr Pazifischer Zeit (16:30 Uhr Östlicher Zeit) eine Telefonkonferenz abhalten, um folgende Themen zu besprechen:
- Finanzielle Leistung im ersten Quartal 2025
- Jüngste geschäftliche Entwicklungen
- Aktuelle Unternehmensinformationen
Interessierte Teilnehmer können der Telefonkonferenz unter folgenden Nummern beitreten:
- Inland: 877-407-6184
- International: 201-389-0877
Die Präsentation wird live übertragen und auf der Investor-Relations-Website des Unternehmens unter www.eksobionics.com im Bereich "Präsentationen & Veranstaltungen" archiviert.
- Scheduled earnings release indicates compliance with SEC reporting requirements and Nasdaq listing standards
- Maintaining investor communication through conference call with both domestic and international access
- None.
SAN RAFAEL, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter of 2025 after the close of trading on Monday, May 5, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments.
To participate in the conference call by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be broadcast live and archived on the Company’s website at www.eksobionics.com under “Presentations & Events” in the Investors section.
About Ekso Bionics®
Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Based upon its industry-leading expertise, the Company focuses on improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.” For more information, visit: www.eksobionics.com.
Contact:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@eksobionics.com
